Valeo Pharma (VPH: CSE) Projecting Record Q2 Revenue As New Drugs Hit The Market. Next Drug Hits Market June 21. Targeting $150M Revenue In 3-4 Years

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.

This model has resulted in the following success:

• 2020 net revenues of $7.5 million
• Q2 is projected to be another record quarter
• Blood Thinner product has just hit the market .. Expected to generate $30M revenue at peak
• Newest Asthma therapies from Novartis expected to hit the market June 21
• Closed $6.6 Million Financing With Insiders Taking ~ 40%

Simply put Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak … and continuing for the foreseeable future. CEO Steve Saviuk believes $VPH could hit $150 MILLION in revenues over the next 3-4 years and is leading the company’s fast expansion of both facilities and personnel.

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.